Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
5.37
+0.33 (6.55%)
At close: Oct 28, 2025, 4:00 PM EDT
5.47
+0.10 (1.86%)
Pre-market: Oct 29, 2025, 4:24 AM EDT
Nuvation Bio Revenue
Nuvation Bio had revenue of $4.83M in the quarter ending June 30, 2025, with 236.79% growth. This brings the company's revenue in the last twelve months to $14.36M, up 900.35% year-over-year. In the year 2024, Nuvation Bio had annual revenue of $7.87M.
Revenue (ttm)
$14.36M
Revenue Growth
+900.35%
P/S Ratio
120.71
Revenue / Employee
$65,250
Employees
220
Market Cap
1.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.87M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NUVB News
- 5 days ago - Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma - Business Wire
- 8 days ago - Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 - Business Wire
- 4 weeks ago - Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer - Business Wire
- 4 weeks ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
- 5 weeks ago - Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - Nuvation Bio: A Rare Gem In The Risky Biotech Space - Seeking Alpha
- 7 weeks ago - Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer - Business Wire
- 7 weeks ago - Top 2 Health Care Stocks That May Plunge This Month - Benzinga